Eligibility criteria were: being prescribed a GLP-1 receptor agonist for management of either for obesity or T2D; being at least 18 years of age; capacity to consent; able to converse and read in fluent English. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.